A researcher is studying the effects of a novel cancer drug on cell division and comparing the new drug to a traditional chemotherapy drug. The traditional drug causes numerous side effects such as nausea, vomiting, hair loss and susceptibility to infections due to low white blood cell counts. The novel drug is a targeted therapy (specifically targets the abnormal protein in the cancer cell) and is likely to reduce side effects that patients experience when treated with traditional chemotherapy. One group of cancer patients was treated with the novel drug and a second group of cancer patients was treated with the traditional chemotherapy drug. Prior and subsequent to treatment, a mitotic index was obtained from a tumor sample from each patient as well as a bone marrow sample (bone marrow cells give rise to all blood cell types including red blood cells and white blood cells). Since this is a double-blind study (neither the patient nor the researcher knows which patients received which drug), the patient samples were labelled with the patients' initials but no information was provided with respect to the drug each patient was receiving. Below is the data for four different patients. Mitotic index was used to measure the effectiveness of each drug treatment. Use the data below to answer the following questions: Patient ID MI bone marrow cells MI bone marrow MI tumor cells MI tumor cells before treatment cells after treatment before treatment after treatment MJ 0.15 0.07 0.44 0.25 JS 0.17 0.15 0.55 0.08 TE 0.14 0.13 0.47 0.05 KR 0.17 0.04 0.51 0.32 С. Which patients would be more susceptible to contracting an infection during treatment? Why?

Human Biology (MindTap Course List)
11th Edition
ISBN:9781305112100
Author:Cecie Starr, Beverly McMillan
Publisher:Cecie Starr, Beverly McMillan
Chapter22: Genes And Disease: Cancer
Section: Chapter Questions
Problem 8SQ: The most common therapeutic approaches to treating cancer include all of the following except...
icon
Related questions
Question
A researcher is studying the effects of a novel cancer drug on cell division and comparing the new drug to
a traditional chemotherapy drug. The traditional drug causes numerous side effects such as nausea,
vomiting, hair loss and susceptibility to infections due to low white blood cell counts. The novel drug is a
targeted therapy (specifically targets the abnormal protein in the cancer cell) and is likely to reduce side
effects that patients experience when treated with traditional chemotherapy. One group of cancer patients
was treated with the novel drug and a second group of cancer patients was treated with the traditional
chemotherapy drug. Prior and subsequent to treatment, a mitotic index was obtained from a tumor sample
from each patient as well as a bone marrow sample (bone marrow cells give rise to all blood cell types
including red blood cells and white blood cells). Since this is a double-blind study (neither the patient nor
the researcher knows which patients received which drug), the patient samples were labelled with the
patients' initials but no information was provided with respect to the drug each patient was receiving. Below
is the data for four different patients. Mitotic index was used to measure the effectiveness of each drug
treatment. Use the data below to answer the following questions:
Patient ID
MI bone marrow cells
MI bone marrow
MI tumor cells
MI tumor cells
before treatment
cells after treatment
before treatment
after treatment
MJ
0.15
0.07
0.44
0.25
JS
0.17
0.15
0.55
0.08
TF
0.14
0.13
0.47
0.05
KR
0.17
0.04
0.51
0.32
C. Which patients would be more susceptible to contracting an infection during treatment? Why?
Transcribed Image Text:A researcher is studying the effects of a novel cancer drug on cell division and comparing the new drug to a traditional chemotherapy drug. The traditional drug causes numerous side effects such as nausea, vomiting, hair loss and susceptibility to infections due to low white blood cell counts. The novel drug is a targeted therapy (specifically targets the abnormal protein in the cancer cell) and is likely to reduce side effects that patients experience when treated with traditional chemotherapy. One group of cancer patients was treated with the novel drug and a second group of cancer patients was treated with the traditional chemotherapy drug. Prior and subsequent to treatment, a mitotic index was obtained from a tumor sample from each patient as well as a bone marrow sample (bone marrow cells give rise to all blood cell types including red blood cells and white blood cells). Since this is a double-blind study (neither the patient nor the researcher knows which patients received which drug), the patient samples were labelled with the patients' initials but no information was provided with respect to the drug each patient was receiving. Below is the data for four different patients. Mitotic index was used to measure the effectiveness of each drug treatment. Use the data below to answer the following questions: Patient ID MI bone marrow cells MI bone marrow MI tumor cells MI tumor cells before treatment cells after treatment before treatment after treatment MJ 0.15 0.07 0.44 0.25 JS 0.17 0.15 0.55 0.08 TF 0.14 0.13 0.47 0.05 KR 0.17 0.04 0.51 0.32 C. Which patients would be more susceptible to contracting an infection during treatment? Why?
Expert Solution
trending now

Trending now

This is a popular solution!

steps

Step by step

Solved in 2 steps

Blurred answer
Knowledge Booster
Genomic studies
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, biology and related others by exploring similar questions and additional content below.
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
Human Biology (MindTap Course List)
Human Biology (MindTap Course List)
Biology
ISBN:
9781305112100
Author:
Cecie Starr, Beverly McMillan
Publisher:
Cengage Learning
Human Heredity: Principles and Issues (MindTap Co…
Human Heredity: Principles and Issues (MindTap Co…
Biology
ISBN:
9781305251052
Author:
Michael Cummings
Publisher:
Cengage Learning